1-4 of 4
Xiang Yao Su, PhD
Close
Sort by
Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1319.
https://doi.org/10.1182/blood-2019-131394
Published: 2019
Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2957.
https://doi.org/10.1182/blood-2019-129962
Published: 2019
Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3846.
https://doi.org/10.1182/blood-2019-129845
Published: 2019
Journal Articles

Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies

Naval Daver, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, Patricia L. Kropf, MD, Karen W.L. Yee, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Elias J. Jabbour, MD, Wendy Stock, Katherine J. Walsh, MD, David A. Rizzieri, MD, Jesus G. Berdeja, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2016) 128 (22): 904.
https://doi.org/10.1182/blood.V128.22.904.904
Published: 2016